<?xml version="1.0" encoding="UTF-8"?>
<p>Several clinical studies have outlined the cannabinoid treatment of spasticity, pain, and hindered bladder control symptoms associated with MS patients. A novel cannabinoid therapy, THC/CBD oromucosal spray (Sativexâ„¢), has been introduced to patients suffering from neuropathic pain that can be difficult to manage with normal pharmaceuticals. A placebo-controlled study found that the spray was able to lessen MS-induced neuropathic pain [
 <xref rid="B83-molecules-25-04078" ref-type="bibr">83</xref>]. The same spray was evaluated for symptomatic relief and was found to cause a decline in spasticity occurrence and severity, and had limited adverse side effects on cognition [
 <xref rid="B84-molecules-25-04078" ref-type="bibr">84</xref>]. This could be due to the critical part CBD plays in diminishing the psychoactive effects of THC. A similar spray provided to MS patients effectively reduced pain and sleep disturbance [
 <xref rid="B85-molecules-25-04078" ref-type="bibr">85</xref>]. When MS patients were provided with THC/CBD extract capsules, daily self-reports of spasm frequency, mobility, and ability to fall asleep were favorably impacted in the active treatment group [
 <xref rid="B86-molecules-25-04078" ref-type="bibr">86</xref>].
</p>
